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In 1925, the pioneering German chemists Ida 
Tackeand Walter Noddack announced the discovery of 
element 75 and named this new element rhenium in 
honor of the river Rhine (Latin Rhenus) [1]. The couple 
would later marry and continue their influential work as 
a team for the remainder of their professional careers. 
Remarkably, the pair also made valuable contributions 
to the discovery of technetium, which along with 
rhenium were the last two missing elements of the 
main periodic table at the time [1]. Both these elements 
belong to group 7 of the periodic table and thus share 
similar chemistry. Being suitable for therapeutic and 
diagnostic purposes respectively, 188Re and 99mTc 
therefore represent an ideal theranostic radionuclide 
pair. It now seems particularly fitting that the current 
partnering of these two radionuclides in a theranostic 
model stems from the discoveries of two partnering 
chemists almost a century ago. 
188Re(T1/217 hours) has excellent physical 
properties as a therapeutic radionuclide. The high 
energy β emission(Eβ max2.12 MeV)has a maximum 
range of 10.4 mm and the accompanying 155 keV 
energy gamma emission (15% abundance) facilitates 
imaging for biodistribution anddosimetry assessment 
[2]. In addition, the on-demand availability of 188Re from 
the tungsten-188(188W)/188Re generator can potentially 
allow daily clinical access in a cost effective manner 
per unit dose [3]. These attractive properties of 188Re 
have been utilized in several clinical applications over 
the last three decades including intra-arterial therapy of 
hepatocellular carcinoma, treatment of metastatic bone 
pain and radiosynoviorthesis [4-6]. 
In 2008 under the visionary guidance of Dr. Ajit 
Padhy, the International Atomic Energy Agency (IAEA)  
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sponsored a multinational trial investigating the safety 
and efficacy of intra-arterial 188Re lipiodol in the 
treatment of inoperable hepatocellular carcinoma 
(HCC) [4]. This large phase II study involving 185 
patients demonstrated that 188Re lipiodol therapy was 
feasible, safe and had promising efficacy with 78% of 
patients achieving either stable disease or objective 
response. This study was made possible only after 
decades of research from many dedicated scientists 
around the world including Dr. F.F (Russ) Knapp Jr 
from Oak Ridge National Laboratory, whose work 
made the 188W/188Re generator a reality and Dr. Jae 
Min Jeong, whose radiopharmaceutical expertise 
helped establish 188Re radiolabeling in kit formulation 
[7]. Following this landmark study, it was unfortunate 
that the momentum in propagating 188Re based 
therapies stalled, mostly due to the availability of other 
radionuclides such as 90Y and 177Lu for developing 
different products [3].  
In this light, Dr. Ajit Padhy and the World 
Association of Radiopharmaceutical and Molecular 
Therapy (WARMTH) embarked on developing a188Re 
therapy program in 2013 at Kovai Medical Center and 
Hospital (KMCH) in Coimbatore, South India. Following 
treatment of the first patient with inoperable HCC at 
KMCH, and under the inspiring leadership of Dr Ajit 
Shinto, a new enthusiasm for this radionuclide therapy 
was born. After 1 year of experience with intra-arterial 
188Re lipiodol therapy for inoperable HCC, their 
stunning data, demonstrating stable disease or 
objective response in 85% of patients, were presented 
at the 2014 World Federation of Nuclear Medicine and 
Biology Congress in Cancun, Mexico. At this moment, 
and as the president of WARMTH, I along with the 
other governing board members unanimously decided 
that WARMTH should actively support propagation of 
this therapeutic technique and a special task force for 
188Re based therapies was created under the 
chairmanship of Dr. Ajit Shinto.  
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After 3 years of hard work we have come a long 
way and it is exciting to highlight some of our 
achievements. We now have a dedicated WARMTH 
188W/188Re generator available at a subsidized cost and 
on a regular basis, a major achievement given the 
previous lack of commercial interest. The first 
dedicated World Rhenium Congress(WRC) has been 
hosted by KMCH in 2015 under Dr. Ajit Shinto in 
collaboration with WARMTH. This landmark congress 
was a resounding success with participation from over 
35 countries and almost 250 delegates in attendance. 
Workshops on 188Re dosimetry, 188W/188Re generator 
radiochemistry, radiopharmaceutical applications and 
quality control have led to six new departments 
initiating 188Re based therapy programs, four from India 
and two from other Asian countries. It is has been most 
fulfilling to see the WARMTH 188Re taskforce plans 
translated into real world treatments within such a short 
period of time.  
Continuing in this spirit, this special issue of the 
International Journal of Nuclear Medicine and 
Research aims to inspire new developments as well as 
build on established applications of 188Re based 
therapy in the nuclear medicine community. The broad 
range of topics presented in this issue and the 
possibility of integrating 188Re into our growing number 
of radiopharmaceutical therapeutic options is 
particularly encouraging for the future of the field. With 
the potential for 188Re based peptide receptor 
radionuclide therapy (PRRT) and prostate-specific 
membrane antigen radioligand therapy (PRLT) a new 
era in radionuclide therapy is within reach. Perhaps, as 
an ideal theranostic combination, the partnership of 
188Re and99mTc is set for a revival! 
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